Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Influenza, Human 2Serology Analysis 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 64Cyclophosphamide 40Bortezomib 37Melphalan 24Lenalidomide 23Thalidomide 17pomalidomide 16fludarabine 12daratumumab 11carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6Prednisone 5Peripheral Blood Stem Cell Transplantation 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4isatuximab 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4Calcium Dobesilate 4liposomal doxorubicin 3ixazomib 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Multiple Myeloma × Influenza Vaccines × Clear all
NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡